Most national health-care systems approve new drugs based on data of safety and efficacy
from large randomized clinical trials (RCTs). Strict selection biases and study-entry criteria of …

The introduction of rituximab biosimilars into healthcare systems can potentially help to
control healthcare costs for the treatment of hematologic malignancies. However, there are …

Immuno-oncologics (IOs) differ from chemotherapies as they prime the patient's immune
system to attack the tumor, rather than directly destroying cancer cells. The IO mechanism of …

Defining patient-to-patient similarity is essential for the development of precision medicine in
clinical care and research. Conceptually, the identification of similar patient cohorts appears …

Background and Objective: Radium-223 dichloride (Xofigo®) is a calcium mimetic agent
approved for the treatment of castration-resistant prostate cancer patients with symptomatic …

Most new drug approvals are based on data from large randomized clinical trials (RCTs).
However, there are sometimes contradictory conclusions from seemingly similar trials and …

Purpose: This study aimed to provide real-world evidence on the characteristics, treatment
patterns, and outcomes of patients with chronic myeloid leukemia (CML) receiving tyrosine …

Purpose: To provide real-world data on the world-wide-web for patient and doctor
awareness. Methods: From December 2017 to January 2020, consecutive patients with …

Abstract Background and Objectives Palbociclib is a cyclin-dependent kinase 4/6 inhibitor
that is approved in the United States for the treatment of hormone receptor‒positive …

Abstract Presently, Gulf Cooperation Council countries are lagging in the generation of real-
world data and use of real-world evidence for patient-centered care compared with the …